by colony formation assays. 4 In comparison to mock and mismatch siRNA-treated cells, siAGF1-treated cells showed at least a threefold decrease in fusion protein and a sixfold decrease in colony forming cells in vitro (Figures 2a and b) . One day after siRNA treatment, cells were either transplanted or stored in liquid nitrogen till transplantation. Transplantations were performed by intraperitoneally injecting 10 6 electroporated cells into sublethally irradiated newborn mice. Total group sizes were 12 animals for the mock group, 11 animals for the active siRNA group and 10 animals for the mismatch control siRNA group. Transplantation of mock-or mismatch siRNAtreated cells resulted in tumour formation in all transplanted animals with a median survival of 50 days (Figure 2c ). In contrast, pretreatment with the active RUNX1/RUNX1T1 siRNA siAGF1 resulted in an extended median survival of 73 days (Po0.02). Notably, three animals of the active siRNA group examined 71 days post-transplantation showed no signs of tumour formation in histological analyses. In a second set of experiments, 2.5 Â 10 5 cells were transplanted 8 h after siRNA electroporation into non-irradiated mice. In this experiment, groups of eight and seven animals were transplanted with active and mismatch siRNA-pretreated cells. This setting resulted in a median survival of 64 and 90 days for the mismatch siRNA and the active siRNA group, respectively. Again, the difference in median survival was statistically significant (Po0.02) suggesting that siRNA-mediated transient reduction of RUNX1/RUNX1T1 causes a substantial decrease in cancer-initiating cells.
In summary, we show that already a transient siRNA-mediated depletion of RUNX1/RUNX1T1 causes a significant increase in median survival in a xenotransplantation model. These findings suggest that RUNX1/RUNX1T1 siRNAs compromises the engraftment and/or self-renewal capacities of t(8;21) leukaemiainitiating cells. Future studies will show whether RNAi-mediated RUNX1/RUNX1T1 suppression during and after leukaemic engraftment may stop or even reverse tumour formation, consequently paving the way for developing therapeutic approaches directly targeting this leukaemic fusion protein.
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Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia Chronic myeloid leukemia (CML) is a clonal disorder associated with chromosomal translocation t(9;22), which produces the Philadelphia chromosome. 1 The fusion gene encodes for the chimeric oncoprotein BCR-ABL, associated with deregulated constitutive tyrosine kinase (TK) activity, leading to leukemogenesis. 1 Imatinib mesylate, the first potent selective inhibitor of BCR-ABL TK, has become the frontline therapy for newly diagnosed CML patients. 1 A large phase III study (the IRIS study) showed that imatinib can induce complete cytogenetic response (CcyR) in 87% of recently diagnosed patients with CML in chronic phase (CP). 2 Imatinib is also effective in advanced phase disease; however, in general, the response is short-lived. 1 Imatinib has also been incorporated into therapeutic regimens in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph þ ALL). The introduction of imatinib markedly reduced the use of allogeneic hematopoietic stem cell transplantation (SCT) in CML in the first CP. SCT is currently reserved for patients in CP after the failure of imatinib or for patients in advanced phase disease. SCT remains the treatment of choice in patients with Ph þ ALL. Most studies have demonstrated that imatinib therapy before allogeneic SCT does not adversely affect the transplantation outcome and that imatinib can also be used successfully as a bridge to SCT in advanced disease. acquired resistance is point mutations in the kinase domain of BCR-ABL that interferes with imatinib binding. 1 These mutations are associated with reactivation of the dysregulated activity of the BCR-ABL protein. Mutations are more commonly found in patients treated in advanced phase disease. Second-generation TK inhibitors have been designed to increase TK activity and to overcome imatinib resistance. Two agents, dasatinib and nilotinib, are currently FDA-approved for the treatment of patients with CML.
Dasatinib is an orally available multitargeted kinase inhibitor that differs from imatinib in that it can bind to both the active and inactive conformations of the ABL kinase domain. Dasatinib also inhibits a broad spectrum of kinases, including Src and Lyn, that partially overlaps with the array of kinases that imatinib inhibits. 4 Recent studies have demonstrated the efficacy and safety of dasatinib in all stages of imatinib-resistant CML and in Ph þ ALL. However, the long-term durability of these responses is uncertain yet, and substantial toxicity has been encountered.
Nilotinib is an orally active derivative of imatinib that has an increased and more selective binding affinity to the ATP pocket of BCR-ABL oncoprotein, resulting in 20-50 times increase of the inhibitory activity of imatinib. 5 Similar to dasatinib, nilotinib produces significant hematologic and cytogenetic responses in all phases of CML and in Ph þ ALL. Both dasatinib and nilotinib have activity against most BCR-ABL kinase domain mutations with the exception of the T315I mutation.
Both agents, similar to imatinib, may result in CCyR, but do not eliminate the quiescent CML stem cell fraction, and thus are not curative.
The approach to patients failing imatinib is still controversial and may include increasing imatinib dose, using a secondgeneration TK inhibitor or allogeneic SCT. 1 Patients may also be given dasatinib or nilotinib for a predefined period of time to test response and be referred to SCT if they fail. Dasatinib or nilotinib can also be used as a salvage regimen for advanced disease before SCT. However, there are only limited data on the effect that prior treatment with nilotinib or dasatinib may have on various SCT outcomes and, in particular, engraftment and SCT-related complications.
We retrospectively analyzed the medical records of patients who had allogeneic SCT for CML or Ph þ ALL following treatment with dasatinib or nilotinib. Patients were selected for SCT on the basis of SCT eligibility and the attending physician's discretion. Initially, patients were treated with these agents on institutional review board-approved open-label, single-arm phase 2 studies, as reported previously. 6, 7 Patients met standard eligibility criteria for these studies, which included documented Ph þ leukemia by conventional cytogenetics, primary or acquired imatinib resistance or intolerance by previously reported criteria and adequate organ function. Patients were subsequently given allogeneic SCT within institutional review board-approved protocols in the participating institutions. All patients with advanced CML or Ph þ ALL were considered SCT candidates irrespective of their response to dasatinib or nilotinib. Patients with CML in CP who were referred to SCT were also analyzed. Generally, responding patients were treated with TK inhibitors until a donor was available or SCT was medically feasible. Patients were re-evaluated before SCT and were required to meet standard eligibility criteria for allogeneic SCT with myeloablative or reduced-intensity conditioning in the participating centers, as determined by the attending physicians.
The analysis included 21 patients, median age 45 years (range: 16-59), 15 men and six women. Nineteen patients had CML and two had Ph þ ALL. Sixteen of 19 patients with CML were in CP, based on previously published criteria; 6,7 their initial therapies included interferon followed by imatinib for no response or progression (n ¼ 8) or, more recently, frontline imatinib (n ¼ 8). One patient presented in accelerated phase and was given frontline imatinib. Two patients presented in blastic crisis (BC) and were given combination chemotherapy followed by imatinib. Two patients had a prior allogeneic SCT and one patient had a prior autologous SCT. The two patients with Ph þ ALL were given combination chemotherapy concomitantly or followed by imatinib.
Upon failure of imatinib-based therapies, two patients were given combination chemotherapy followed by TK inhibitor (both with lymphoid BC), whereas all others were given one of the TK inhibitors alone, up front. Thirteen patients were given dasatinib (70 mg Â 2/day, orally), five patients were given nilotinib (400 mg Â 2/day, orally) and three had dasatinib followed by nilotinib due to no response. Mutation status at the start of therapy was available in 12 patients. Six mutations have been detected in five patients, including Y253H (n ¼ 2), E255 K (n ¼ 2), L387N (n ¼ 1) and T315I (n ¼ 1). Response to TK inhibitor treatment was assessed on the basis of previously reported criteria. 6, 7 Five patients were in CP1; after TK inhibitor treatment, two had CCyR, one had partial CyR (PCyR) and two had less than a major CyR (MCyR); none progressed before SCT. Six patients were in accelerated phase (n ¼ 5) or CP2 (n ¼ 1). Three patients achieved complete hematologic response, one of them with CCyR and one with PCyR. The patient with PCyR lost his CyR while waiting for an unrelated donor SCT. Three patients did not respond and one even progressed to BC before SCT. Ten patients had BC (n ¼ 8) or Ph þ ALL in relapse (n ¼ 2). Five patients achieved complete hematologic response, which included a CCyR in two. However, two of them relapsed before SCT and were transplanted in BC. One patient had a minor hematologic response and maintained it until SCT. Four patients had no hematological response. All received additional combination chemotherapy after TK inhibitor failure and three achieved minor hematologic response. In all, 9 of 16 patients with advanced CML/Ph þ ALL (56%) achieved a hematological response and seven (44%) have maintained it until SCT. The most recent TK inhibitor was given for a median of 90 days (range: 31-720) and was discontinued a median of 24 days (range: 1-90) before the start of conditioning. Most patients stopped TK inhibitor treatment a few days before conditioning for allogeneic SCT and four patients stopped it before another course of combination chemotherapy.
The donor was an HLA-matched sibling (n ¼ 7), matchedunrelated (n ¼ 13) or haploidentical (n ¼ 1). Patients were given myeloablative (n ¼ 14) or reduced-intensity conditioning (n ¼ 7) based on eligibility criteria in the local institution and at the attending physician's discretion. The typical myeloablative regimens used were the combination of total body irradiation (total 12 Gy) and high-dose cyclophosphamide (total dose 120 mg/kg), or high-dose IV busulfan (total dose 12.8 mg/kg) and cyclophosphamide (total dose 120 mg/kg, ivBuCy). The typical reduced-intensity conditioning was the combination of fludarabine (total dose150 mg/m 2 ) and reduced-dose busulfan (total dose 6.4 mg/kg). Most patients were also given antithymocyte globulin (Fresenius) at a total dose of 15 mg/kg. Graftversus-host disease (GVHD) prophylaxis consisted of cyclosporine A and a short course of methotrexate (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6) or complete T-cell depletion (in haploidentical SCT). Nineteen patients were given granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cell graft with a median of 7.5 (range: 1.8-24) Â 10 6 CD34 þ cells/kg, and two patients had bone marrow transplantation.
All patients engrafted successfully, reaching absolute neutrophil count 40.5 Â 10 9 /l on day þ 18 (range: 11-37) and unsupported platelet count 420 Â 10 9 /l on day þ 18 (range: 11-42). One patient had primary nonengraftment but was salvaged with additional bone marrow from the original donor. Chimerism at approximately 1 month after SCT was 99.4-100% in all patients. One patient had late graft rejection, 9 months after SCT, concomitantly with molecular relapse and was salvaged with a second allograft.
Transplant-related toxicities were relatively infrequent. Eight patients developed severe (grade III) mucositis. Two patients had reversible veno-occlusive disease of the liver, and there were no other significant organ toxicities. There was no apparent increase in the incidence of bacterial or fungal infections. Acute GVHD was observed in eight patients (43%; grade I: one patient, grade II: six patients and grade III-IV: one patient). There was no death attributed to acute GVHD. Chronic GVHD occurred in 10 of 18 evaluable patients (55%; limited: five, extensive: five) and resulted in one death. In all, the cumulative incidence of nonrelapse mortality was 7% (95% confidence interval (CI), 1-48).
Nineteen patients achieved complete hematologic response after SCT. Two patients had progressive disease immediately following SCT. One was a patient with advanced relapse of Ph þ ALL having a second allogeneic SCT, and the other was transplanted in resistant BC. Thirteen patients with follow-up of more than 3 months after SCT achieved complete molecular response. Three patients achieved complete hematologic response with less than major molecular response, and three have a yet shorter follow-up. With a median follow-up of 14 months (range: 1-31), 15 patients are alive, whereas six died, five of disease progression and one of chronic GVHD. Three additional patients relapsed and are currently alive. One relapsed in overt Ph þ ALL and is alive following additional courses of chemotherapy. Two had molecular relapse; one is in prolonged remission following a second allograft and the other resumed nilotinib therapy and is in continuous complete molecular response. In all, the cumulative incidence of relapse was 34% (95% CI, 17-65). The 2-year estimates of overall survival and disease-free survival are 64% (95% CI, 41-87; Figure 1 ) and 46% (95% CI, 22-71), respectively. Table 1 outlines the factors predicting disease-free survival. The most significant poor prognostic factor was SCT during BC or active Ph þ ALL. Only one of four such patients is alive and with a short follow-up. Any hematological response to dasatinib or nilotinib or chemotherapy was associated with improved outcome. There was a trend for better outcome in patients in CP1 who had no history of disease progression. The five patients with CML in CP1 are all alive and currently disease-free (one after a second allograft). This trend did not reach statistical significance most probably due to low patient number. Mutation status did not affect outcome after SCT. The small patient groups did not allow for a meaningful multivariable analysis.
Our data suggest that the use of dasatinib and nilotinib does not adversely affect the outcome of a subsequent allogeneic SCT. In particular, there is no evidence for increased risks for graft failure, treatment-related organ toxicity or GVHD. Nonrelapse mortality in the current series was only 7%, comparing favorably with the rates expected in a group of patients with a high proportion of patients with advanced disease and with alternative donors.
The introduction of imatinib had a profound effect on the use of allogeneic SCT in CML, with a marked decrease in the number of transplants, but an increase in the proportion of transplants performed in advanced disease. Most patients receive a trial of imatinib before proceeding to SCT. The outcome of patients after imatinib failure is unfavorable and depends to a large extent on the phase of disease at resistance/progression. Kantarjian et al. 8 analyzed the outcome of 374 patients after imatinib failue. The 3-year overall survival was 72% in 88 patients progressing in CP, 30% in 130 patients progressing in accelerated phase and 7% in 156 patients progressing in BC.
Allogeneic SCT remains an important salvage option for patients who develop resistance to imatinib through BCR-ABL kinase domain mutations. SCT outcome depends most significantly on disease status at transplantation. SCT in overt BC is associated with dismal outcome; however, results may improve considerably, if a second CP can be restored with salvage therapy. Dasatinib and nilotinib produce significant hematologic and cytogenetic responses in imatinib-resistant and -intolerant patients, and responses are often durable. Response rates are higher than expected with combination chemotherapy, especially in myeloid BC. [4] [5] [6] [7] The current analysis is not designed to assess response to dasatinib or nilotinib, as patients are analyzed on the basis of SCT eligibility, and analysis may be biased by nonresponders who have not been referred to SCT. However, 9 of 16 patients with advanced disease achieved a hematologic response (56%) and seven (44%) maintained it until SCT. These rates are similar to those published in the large series. Patients achieving any hematologic response had a much favorable outcome compared to the dismal outcome of those transplanted in overt BC, estimated 2-year disease-free survival 56% and 0%, respectively (Table 1 , P ¼ 0.01). These survival rates for responding patients are promising. One can conclude that dasatinib and nilotinib treatment may allow effective salvage therapy with reduction of leukemia burden and SCT in a less advanced phase, and thus opens a window of opportunities for SCT in patients with advanced disease.
The approach to patients in imatinib-resistant CP is more controversial. These agents may be used as the preferred treatment and SCT reserved for nonresponders or they may be used as a bridge for SCT. 1 In our small series, all five patients in CP given dasatinib or nilotinib and a subsequent SCT are alive and currently disease-free (one after a second allograft).
Prior therapies may affect toxicities associated with a subsequent SCT, by inducing specific organ toxicities or by Letters to the Editor immune modulation. Historically, prior treatment with busulfan was associated with increased pulmonary and hepatic toxicity. Studies analyzing the impact of prior interferon therapy on SCT outcome reported conflicting results. Some studies showed no effect, whereas others showed increased treatment-related toxicity (graft failure and GVHD), which depended on the duration of interferon treatment and on the interval between discontinuation and SCT. The pathogenesis is unknown. It is speculated that immune modulation induced by prolonged interferon therapy, such as upregulation of expression of HLA class I and II molecules, may explain some of these observations. Stromal damage may relate to the increased incidence of graft failure. Prior imatinib therapy is not associated with adverse effect on SCT outcome. 3, 9 Dasatinib and nilotinib are generally well tolerated. The most significant side effect is myelosuppression, which is effectively managed with dose modification. Pretransplant myelosuppression should not affect SCT outcome, unless severe and associated with serious infections, which is rarely the case. However, therapy should be stopped before conditioning so as to not endanger engraftment. Dasatinib seems to have a wider spectrum of adverse effects than nilotinib most probably as it is a less specific TK inhibitor. The most common nonhematologic adverse effect is pleural effusion that, if severe, may affect patient performance status and eligibility for SCT. Nilotinib may cause elevation of indirect bilirubin and rashes that are not expected to affect subsequent SCT. 9 Hepatic toxicity has been reported with both agents but is generally mild. We observed only two patients with reversible veno occlusive disease (VOD) of the liver. This incidence is what can be expected in allogeneic SCT and especially in patients with advanced disease, and it cannot be directly attributed to prior TK inhibiotor treatment. In all, dasatinib and nilotinib treatment may have a more favorable toxicity profile than combination chemotherapy, and may better preserve patient performance status and organ function, limiting SCT-induced organ toxicity.
Only one patient in this study had grade III-IV acute GVHD, and there was only one death attributed to chronic GVHD. Some studies showed reduced rates of chronic GVHD in imatinib-pretreated patients compared with historical controls. 9 The mechanism of this observation is speculative. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation and specific CD8 þ T-cell responses. Imatinib also inhibits dendritic cell development and function, impairing their ability to elicit primary T-cell responses or responses to recall antigens. Emerging data show that nilotinib may have similar immunesuppressive effects. These effects are mediated through inhibition of the phosphorylation of ZAP-70, Lck, ERK 1/2 and nuclear factor-kB signaling transduction pathways. It is unclear how these effects persist after SCT, when the patient is off therapy. GVHD is caused by presentation of self-antigens by host antigen presenting cells to donor T cells. One can speculate that this process is inhibited by prior TK inhibitor treatment. Imatinib was stopped in most studies for a short period before conditioning, and this effect on GVHD may not persist after a longer interval of discontinuation.
In summary, prior treatment with dasatinib and nilotinib may allow SCT in patients with CML or Ph þ ALL in a less advanced disease phase and probably does not increase the incidence of transplant-related organ toxicity, engraftment failure or GVHD. Treatment may be a safe and effective salvage therapy for patients after failure of imatinib and before SCT. However, these observations should be interpreted with caution due to the small number and heterogeneous characteristics of this patient group. A larger series of patients will be needed to confirm these preliminary observations. Letters to the Editor
